Peptide RX

back to claim graph

proof receipt / target

OX1R

Orexin receptor type 1

grade B status sleep_circadian receipt 96e6ce7cdf34 proof 33%

what this node claims

OX1R

Orexin receptor type 1

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 21%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    GPCR_class_A
    functional sites
      gene symbol
      HCRTR1
      go terms
        uniprot
        O43613

        AlphaFold metrics visual

        Confident backbone model

        78.8

        425 residues / min 27.14 / max 98.62 / source alphafold db

        PAE matrix for linked target
        Very high 54.4% 231 residues / >=90
        Confident 17.2% 73 residues / 70-89
        Low 9.4% 40 residues / 50-69
        Very low 19.1% 81 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 425 of 425 residues.

        • residues 376-425 / mean 35.62
        • residues 245-276 / mean 50.71
        • residues 1-28 / mean 45.25
        • residues 189-198 / mean 61.26
        proof debt register

        Visible limits, not hidden cleanup.

        21%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:889d5d7f-d49f-40ea-b271-460d03346936 -> fold:81b032f8-5dcc-4ebe-94cd-29297c822490 folds_to / B / 0.788

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.